Considering these findings, it appears that the elevated APO-TCN2 in our 2-year survival cohort, with no difference in HOLO-TCN2 levels, mirrors the heightened systemic immune activity seen in common autoimmune disorders. Here, TCN2 is linked to autoimmune disease.